BioWorld MedTech

Nov. 16, 2015

View Archived Issues

Mindray merger a precursor to U.S. stock exchange delisting, return to private status

HONG KONG — One of the biggest Chinese medical device companies is undergoing a $3 billion delisting from the U.S. market as it paves the way to head back to its home market and the possibility of more access to investment. Read More

CT colongraphy is again gaining traction on Hill

Read More

Mimedx says market overreacted to FDA's recent HCT/P guidance

Read More

Colombia defining technological device evaluation guidelines

Read More

M&A activity increases as industry gets personal

Read More

AHA, Google Life Sciences enter $50M research collaboration

Read More

Products

Read More

Thermo Fisher authorizes $1 billion share repurchase

Read More

Keeping you up to date on recent developments in Neurology

Read More